Premium
LONG‐TERM FOLLOW‐UP AND BIOMARKER ANALYSES OF BRENTUXIMAB VEDOTIN AND DHAP IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS: THE HOVON/LLPC TRANSPLANT BRAVE STUDY
Author(s) -
Driessen J.,
Kersten M. J.,
Visser L.,
den Berg A.,
Zijlstra J. M.,
Tonino S. H.,
Zwezerijnen G. J.,
Boellaard R.,
Lugtenburg P. J.,
Hutchings M.,
Nijland M.,
Liu R. D.,
Morschhauser F.,
Brice P.,
Gastinne T.,
Jong D.,
Hagenbeek A.,
Plattel W. J.,
Diepstra A.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.102_2880
Subject(s) - medicine , brentuximab vedotin , oncology , reed–sternberg cell , clofarabine , biomarker , anaplastic large cell lymphoma , refractory (planetary science) , lymphoma , gastroenterology , cytarabine , chemotherapy , hodgkin lymphoma , biology , biochemistry , astrobiology